Otsuka Corporation

4768

JP3188200004

OTSUKA CORPORATION is a Japan-based company mainly engaged in the sale of system equipment, the installation support and maintenance services. The Company operates through two business segments. System Integration segment conducts consulting, hardware and software sales, contract software development, equipment installation and network construction. Service & Support segment provides office supply, maintenance services, as well as business support services. The Company is also involved in the car maintenance business and insurance business.

Sector

IT Services & Consulting

Calendar

2023-12-27 - Final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for Otsuka Corporation

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6,073JPY

Average target price

6,658.18JPY

Spread / Average Target

+9.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Technology Consulting & Outsourcing Services

	1st Jan change	Capi.
OTSUKA CORPORATION	+46.16%	7 780 M $
VERISK ANALYTICS, INC.	+35.00%	35 193 M $
SS&C TECHNOLOGIES HOLDINGS, INC.	+9.49%	14 274 M $
SAMSUNG SDS CO.,LTD.	+33.09%	10 024 M $
POSCO DX COMPANY LTD.	+740.00%	6 153 M $
REPLY S.P.A.	-1.31%	4 308 M $
CHINDATA GROUP HOLDINGS LIMITED	+6.02%	3 120 M $
DHC SOFTWARE CO.,LTD.	+17.14%	2 955 M $
NS SOLUTIONS CORPORATION	+45.78%	2 902 M $
CHINA TRANSINFO TECHNOLOGY CO., LTD	+35.54%	2 695 M $

Technology Consulting & Outsourcing Services

Market Closed - Japan Exchange Other stock markets 01:00:00 2023-12-04 am EST			5-day change	1st Jan Change
6,073 ^JPY	+0.53%		+2.05%	+46.16%

Nov. 27	Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	MT
Nov. 18	US FDA approves Medtronic's blood pressure treatment device for use	RE

Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings	Nov. 27	MT
US FDA approves Medtronic's blood pressure treatment device for use	Nov. 17	RE
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan	Nov. 13	MT
FDA Approves Otsuka's Innovative Paradise Ultrasound System for Hypertension Treatment	Nov. 09	MT
US FDA approves Otsuka's blood pressure treatment device for use	Nov. 07	RE
Otsuka Holdings’ Attributable Profit up 45.6% in Nine-Month Period as Revenue Growth More than Offsets Impairment Losses	Nov. 01	MT
Lupin Gets US FDA Final Nod for Tolvaptan Tablets	Oct. 05	MT
Certain Shares of Nihon Knowledge Co,Ltd. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	Sep. 19	CI
Mindset Pharma Agrees to be Bought by Otsuka Pharmaceutical	Aug. 31	MT
Otsuka's Paradise Renal Denervation Device Receives Favorable Pre-Market Approval Votes from FDA Panel	Aug. 24	MT
Renova Signs 30-Year Purchase Agreement to Sell Non-FIT Non-Fossil Certs to Otsuka	Aug. 24	MT
First Solar Power G.K. Concludes an Environmental Value Sale and Purchase Agreement	Aug. 22	CI
US FDA panel backs Otsuka's blood pressure treatment device	Aug. 22	RE
US FDA Staff Reviewers Say No Issues Found With Medtronic, Otsuka Blood Pressure Devices	Aug. 18	MT
US FDA staff raise no concerns about Otsuka, Medtronic blood pressure devices	Aug. 18	RE
Otsuka Holdings’ Attributable Net Profit Up 47% in Q2	Aug. 02	MT
Jefferies Adjusts Otsuka’s Price Target to 6,900 Yen From 5,900 Yen, Keeps at Buy	Aug. 02	MT
Otsuka Holdings Raises H1 Results Forecast; Shares Up 3%	Jul. 25	MT
Japan's Nikkei slips ahead of BOJ meeting, automakers top losers	Jul. 25	RE
Longeveron Names Lisa Locklear as CFO	Jul. 20	MT
Glass Lewis ESG Controversy Alert: Taisei Corporation	Jun. 20	MT
Earnings Fever Powers Japanese Equities Ship; Otsuka's Q1 Attributable Profit Zooms 164%	May. 15	MT
Otsuka's Q1 Attributable Profit Zooms 164%; Shares Rise 3%	May. 15	MT
Lundbeck Wins Expanded US FDA Nod for Antipsychotic Drug	May. 11	MT
Aurinia Pharmaceuticals Wins Swiss Approval for Kidney Disease Drug	May. 03	MT